Lista de obras - Eva M Ciruelos - Dominio Público Uruguay

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

artículo científico publicado en 2016

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

scientific article published on 22 September 2020

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

artículo científico publicado en 2016

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Adjuvant ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Adjuvant therapy after preoperative treatment for breast cancer.

artículo científico publicado en 2009

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

artículo científico publicado en 2015

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance

artículo científico publicado en 2016

Behaviour of breast cancer molecular subtypes through tumour progression

artículo científico publicado en 2012

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

artículo científico publicado en 2014

Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain

artículo científico publicado en 2006

Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.

artículo científico publicado en 2003

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

artículo científico publicado en 2015

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

scientific article published on 20 April 2020

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases

artículo científico publicado en 2016

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

artículo científico publicado en 2022

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab.

artículo científico publicado en 2009

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

artículo científico publicado en 2015

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

artículo científico publicado en 2013

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO

artículo científico publicado en 2011

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients.

artículo científico publicado en 2009

European inter-institutional impact study of MammaPrint

scientific article published on 28 March 2014

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer

artículo científico publicado en 2014

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

scientific article published on 13 March 2020

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

artículo científico publicado en 2014

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

artículo científico publicado en 2009

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value.

artículo científico publicado en 2011

Implication of miRNA in the diagnosis and treatment of breast cancer.

artículo científico

It is not time to stop progesterone receptor testing in breast cancer.

artículo científico publicado en 2005

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer

artículo científico publicado en 2014

Lobular carcinoma of the breast: outcome of 205 patients

artículo científico publicado en 2011

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

artículo científico publicado en 2012

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

artículo científico publicado en 2009

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

artículo científico

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

artículo científico publicado en 2014

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer.

artículo científico publicado en 2009

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

article

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

scientific article published on 30 September 2019

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

artículo científico publicado en 2013

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

scientific article published on 01 February 2008

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

artículo científico publicado en 2011

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

artículo científico publicado en 2014

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

artículo científico publicado en 2020

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

scientific article published on 01 May 2019

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy.

artículo científico publicado en 2011

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

artículo científico publicado en 2003

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

artículo científico publicado en 2006

Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review

artículo científico publicado en 2019

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

artículo científico

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

artículo científico

SEOM clinical guidelines in early-stage breast cancer 2015

artículo científico publicado en 2015

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

artículo científico publicado en 2012

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, [...]

artículo científico publicado en 2016

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

artículo científico publicado en 2017

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer ⬇️

artículo científico publicado el 12 de marzo de 2012

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

artículo científico publicado en 2018

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

artículo científico publicado en 2014

The need for post-mastectomy radiotherapy in patients with IBC

artículo científico publicado en 2015

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer

artículo científico publicado en 2010

The present and future of gene profiling in breast cancer.

artículo científico publicado en 2012

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

artículo científico

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

artículo científico publicado en 2010

Trastuzumab in small tumours and in elderly women.

artículo científico

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

artículo científico publicado en 2016

microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples.

artículo científico publicado en 2011

Lista de obras de Eva M Ciruelos

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Adjuvant ovarian suppression in premenopausal breast cancer

Adjuvant therapy after preoperative treatment for breast cancer.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance

Behaviour of breast cancer molecular subtypes through tumour progression

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain

Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastases

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients.

European inter-institutional impact study of MammaPrint

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value.

Implication of miRNA in the diagnosis and treatment of breast cancer.

It is not time to stop progesterone receptor testing in breast cancer.

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer

Lobular carcinoma of the breast: outcome of 205 patients

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer.

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy.

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review

Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

SEOM clinical guidelines in early-stage breast cancer 2015

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, [...]

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer ⬇️

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

The need for post-mastectomy radiotherapy in patients with IBC

The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer

The present and future of gene profiling in breast cancer.

The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

Trastuzumab in small tumours and in elderly women.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

microRNA and protein expression in breast cancer formalin-fixed paraffin-embedded samples.